Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitorMatthew R. Janes, Lomon So, Jing Chen et al.|Nature Medicine|2010Cited by 338
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsMichael G. Kharas, Matthew R. Janes, Vanessa M. Scarfone et al.|Journal of Clinical Investigation|2008Cited by 150